
Job title - Group Product Manager - Particle Analyzer Product Line
Location - Malvern – Onsite with 20-30% global travel
We are seeking an experienced and strategic Group Product Manager to lead our global Particle Analyzer product portfolio. Reporting directly to the GM / VP of the Particle & Biophysical Product Line, you will be accountable for defining and executing long-term product strategy, driving sustainable portfolio growth, and delivering customer-focused innovation across one of our most important technology platforms.
As the business owner for the Particle Analyzer portfolio, you will translate market opportunities, customer needs, and technological advancements into compelling product roadmaps that strengthen market leadership and create long-term value. Working closely with R&D, Commercial, Applications, Operations, Service, and regional leadership teams, you will ensure innovation investments are aligned with customer requirements and business objectives.
This is a high-impact leadership opportunity for an experienced product management professional with strong commercial acumen, strategic vision, and a passion for bringing innovative scientific instrumentation solutions to market
We provide market-leading, material characterization technologies for the world's most innovative companies, academic institutions, and government laboratories in the analytics of advanced materials.
We support our customers through their biggest challenges, from developing lifesaving vaccines to sustainable fuels. We wake up every day to delight our customers through innovation, high-quality solutions and workflows, and excellence in customer satisfaction.
We are a recognized leader for quality and insights in material characterization; winning customers with performance and keeping them with service. With more than 2,000 employees operating in over 20 countries across the world, and R&D sites in North America, Europe and Asia.
We are part of Spectris, a company which combines precision with purpose to equip customers to solve some of their greatest challenges to make the world cleaner, healthier and more productive. In 2025, Spectris acquired Micromeritics as part of Malvern Panalytical.

Together we are a powerful and highly complementary combination of market leading technologies.
We are the toolmakers for the world's most innovative companies, academic institutions, and government laboratories.
More than 92,000 of our instruments are used every day in our customers’ laboratories. Customers value us not only for the power of our analytical technologies, but also for the depth of our expertise. We are their partners in discovery.
Customers see the difference when they use our instruments and feel the difference when they deal with our people.
Malvern Panalytical instruments analyze the chemical, physical and structural nature of materials, from proteins to polymers and semiconductors to minerals. Our leading technologies measure particle size, shape, concentration and zeta potential, biomolecular interactions and stability, elemental concentrations and crystallographic structure.
Micromeritics manufactures systems for the characterization of particles, powders, and porous materials for a wide- range of end markets including catalysts, chemicals, building materials, clean-tech and battery. Our leading technologies measure surface area, porosity, density, adsorption and particle activity.
SciAps specializes in portable X-ray fluorescence (XRF), laser-based (LIBS) and near-infrared (NIR) analyzers to measure any element in any environment. SciAps is the Center of Excellence for our handheld instruments.
We have a global footprint with R&D and manufacturing sites in North America, Europe, and Asia. We are more than 2,500 employees in a customer-focused organization with sales and service offices in 20 countries, all committed to delivering expert and responsive customer support.
We are committed to achieving Net Zero in our operations by 2030, and across our total value chain by 2040.
We are part of Spectris plc, a publicly traded FTSE 250 company.